Intrathecal pemetrexed improves survival outcomes in previously treated EGFR-mutant advanced non-small-cell lung cancer with leptomeningeal metastases

培美曲塞 医学 肺癌 突变体 肿瘤科 鞘内 内科学 癌症 癌症研究 化疗 顺铂 生物 外科 基因 生物化学
作者
Liqun Li,Zhe Huang,Yangqian Chen,Hongzhi Ma,Xiaoquan Chen,Huan Yan,Haoyue Qin,Yuda Zhang,Xing Y. Zhang,Wenjuan Jiang,Zhan Wang,Lin Zhang,Fanxu Zeng,Zhiguo Zhou,Xingxiang Pu,Nong Yang,Liang Zeng,Yongchang Zhang
出处
期刊:Heliyon [Elsevier BV]
卷期号:10 (24): e40703-e40703 被引量:9
标识
DOI:10.1016/j.heliyon.2024.e40703
摘要

Objective This study assessed the impact of intrathecal pemetrexed (IP) in managing leptomeningeal metastases (LM) in previously treated patients with EGFR -mutant advanced non-small cell lung cancer (NSCLC). Methods We analyzed the clinical and survival outcomes of 50 patients with LM who received 50 mg IP after disease progression with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment between September 2021 and September 2023 at the Hunan Cancer Hospital. Treatment response was evaluated based on improvement in neurological symptoms/signs and Karnofsky Performance Status (KPS) scores. We also evaluated the overall survival (OS), intracranial progression-free survival (I-PFS), and extracranial progression-free survival (E-PFS). Next generation sequencing (NGS) was employed to explore the underlying mechanisms of LM after EGFR-TKIs resistance. Results IP treatment was associated with a 64 % clinical response rate, median I-PFS of 5.3 months (95 % confidence intervals [CI], 1.4–9.2), E-PFS of 8.0 months (95 % CI, 2.2–13.8), and OS of 12.0 months (95 % CI, 9.6–14.4). Compared with non-responders, responders to IP demonstrated significantly prolonged I-PFS (11.2 months vs. 1.0 month; hazard ratio [HR]: 0.15, 95 % CI: 0.06–0.39), E-PFS (11.2 months vs. 3.0 months; HR: 0.24, 95 % CI: 0.10–0.57), and OS (15.5 months vs. 3.8 months; HR: 0.22, 95 % CI: 0.08–0.58) (all P < 0.001). Adverse events(AEs) primarily consisted of myelosuppression (54 %) and hepatic damage (24 %), but were manageable and did not result in any deaths. EGFR mutations were consistent between cerebrospinal fluid (CSF) and primary tumors in 100 % of cases. CSF also exhibited genetic variations such as EGFR mutations/amplifications and alterations in TP53 , CDKN2A , MET , and CDK6 . Conclusion IP represents a potentially viable treatment option for managing LM in patients with EGFR-TKI-resistant EGFR -mutant advanced NSCLC. Clinical responses as measured by the improvement of neurological symptoms/signs and KPS scores were associated with favorable survival outcomes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
TSW发布了新的文献求助10
1秒前
向师完成签到,获得积分10
1秒前
田様的应助被复杂代萱采纳,获得10
1秒前
1秒前
一心怡意发布了新的文献求助30
3秒前
Clover完成签到,获得积分10
3秒前
六道发布了新的文献求助10
3秒前
苏以禾完成签到 ,获得积分10
3秒前
小陈完成签到,获得积分10
3秒前
Owen的应助被向着阳光奔跑采纳,获得10
4秒前
5秒前
老迟到的羊完成签到 ,获得积分10
5秒前
eating完成签到,获得积分10
6秒前
乐乐的应助被小马同学采纳,获得10
6秒前
6秒前
6秒前
6秒前
单薄开山发布了新的文献求助10
7秒前
丁真人发布了新的文献求助10
7秒前
Passskd完成签到,获得积分10
7秒前
8秒前
wxg完成签到,获得积分10
8秒前
zhaoben发布了新的文献求助10
9秒前
科研通AI6.3的应助被TSW采纳,获得10
9秒前
10秒前
wst1988完成签到,获得积分0
10秒前
Tsuns完成签到,获得积分10
10秒前
郭娅楠发布了新的文献求助10
11秒前
133完成签到 ,获得积分10
11秒前
11秒前
11秒前
12秒前
syvshc的应助被calm采纳,获得10
13秒前
13秒前
小红发布了新的文献求助10
13秒前
13秒前
桃子汽水发布了新的文献求助10
14秒前
14秒前
黄智清完成签到,获得积分10
14秒前
笨笨山芙完成签到,获得积分0
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183792
求助须知:如何正确求助?哪些是违规求助? 9573020
关于积分的说明 21828776
捐赠科研通 7780959
什么是DOI,文献DOI怎么找? 3434116
关于科研通互助平台的介绍 2558301
邀请新用户注册赠送积分活动 2480611